ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/QLD/4215-Southport-Tasman-Oncology
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
12
trial(s) found.
NCT06764485
Advanced
Phase 3
Recruiting
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) -
rechARge
dual AR degrader antagonist
taxane
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2560 - Campbelltown - GenesisCare Campbelltown
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06750185
Advanced
Phase 1
Recruiting
A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors (
BNT317-01
)
cancer therapy,undisclosed mechanism
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Tasman Oncology
NCT06730750
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors (
CA238-0001
)
anti-VEGF monoclonal antibody
unknown drug class
Solid tumour
QLD
4215 - Southport - Tasman Oncology
NCT06623422
Curative
Phase 3
Recruiting
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) (
V940-009
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
Non-small cell lung cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.9016 - Dunedin - Dunedin Hospital
NCT06475937
Advanced
Phase 1
Recruiting
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients With Advanced Solid Tumors (
DM001001
)
bispecific-EGFR/Trop2 antibody-drug conjugate
Breast cancer
Non-small cell lung cancer
Solid tumour
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Tasman Oncology
NCT06346067
Advanced
Phase 3
Recruiting
A Randomized, Open-label Phase III Study in Patients With Previously Treated Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma Comparing the Combination of Naporafenib + Trametinib to Physician's Choice of Therapy (Dacarbazine, Temozolomide or Trametinib Monotherapy) With a Dose Optimization lead-in [SEACRAFT-2] (
ERAS-254-02
)
MEK inhibitor
RAF dimer inhibitor
alkylating agent
Melanoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - Hollywood Private Hospital
NCT06022029
Haem
Phase 1
Recruiting
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas (
ON-5001
)
STING agonist
anti-PD-1 monoclonal antibody
Bladder cancer
Cancer
Carcinoma
Cervical cancer
Diffuse large B-cell lymphoma
Follicular lymphoma
Head and neck squamous cell carcinoma
Lymphoma
Mantle cell lymphoma
Skin cancer
Triple-negative breast cancer
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4215 - Southport - Tasman Oncology
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05794906
Curative
Phase 3
Recruiting
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer (
ARASTEP
)
antiandrogen,nonsteroidal,second generation
placebo
Prostate cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2076 - Wahroonga - Sydney Adventist Hospital
2170 - Liverpool - Liverpool Hospital
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (WITHDRAWN)
2109 - North Ryde - Macquarie University Hospital (WITHDRAWN)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (WITHDRAWN)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (WITHDRAWN)
VIC
3002 - East Melbourne - Epworth Freemasons
3051 - Melbourne - Australian Prostate Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3000 - Melbourne - Peter MacCallum Cancer Centre (WITHDRAWN)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (WITHDRAWN)
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4215 - Southport - Tasman Oncology (WITHDRAWN)
4655 - Urraween - Cancer Care Service, Hervey Bay Hospital (WITHDRAWN)
4670 - Bundaberg - Bundaberg Hospital, Genesis Cancer Care (WITHDRAWN)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NA
NA
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05544552
Advanced
Phase 1 / Phase 2
Recruiting
A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (
SURF301
)
FGFR3 inhibitor
Bladder cancer
Cancer
Carcinoma
FGFR3:alteration
Solid tumour
Urothelial carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - Linear Clinical Research
NCT05081609
Advanced
Phase 1 / Phase 2
Recruiting
IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (
IL-Believe
)
TLR7/TLR8 agonist
anti-PD-1 monoclonal antibody
Breast cancer
Cervical cancer
Melanoma
Non-small cell lung cancer
Platinum resistant ovarian cancer
Small-cell lung cancer
Solid tumour
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
5065 - Toorak Gardens - Burnside War Memorial Hospital (TERMINATED)
NCT04305054
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B (
3475-02B
)
anti-PD-1 monoclonal antibody
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
QLD
4215 - Southport - Tasman Oncology (COMPLETED)
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT03486873
Advanced
Phase 3
Recruiting
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (
3475-587
)
anti-PD-1 monoclonal antibody
Haematological malignancy
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre
2060 - North Sydney - Mater Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Tasman Oncology
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (12)
Recruitment Country and State
QLD (11)
NSW (10)
VIC (9)
WA (8)
SA (5)
NZ (3)
TAS (1)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (4)
Phase 3 (5)
Trial Type
Advanced (9)
Curative (2)
Haem (1)
Cancer Therapy Class
PD-1
42%
PD-1/PD-L1
42%
VEGF
25%
AR
17%
androgen axis
17%
LAG3
17%
CYP17A1
8%
BRAF
8%
MEK
8%
RAF
8%
STING
8%
FGFR
8%
FGFR3
8%
ERBB2
8%
TLR7/TLR8
8%
CTLA4
8%
TIGIT
8%
PARP
8%
Facility
4215 - Southport - Tasman Oncology (12)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (6)
3000 - Melbourne - Peter MacCallum Cancer Centre (5)
2109 - North Ryde - Macquarie University Hospital (4)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (3)
4120 - Greenslopes - Greenslopes Private Hospital (3)
3168 - Clayton - Monash Medical Centre (3)
2076 - Wahroonga - Sydney Adventist Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
2170 - Liverpool - Liverpool Hospital (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (2)
2560 - Campbelltown - GenesisCare Campbelltown (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
6009 - Nedlands - One Clinical Research (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
6009 - Nedlands - Hollywood Private Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
2031 - Randwick - Prince of Wales Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
3002 - East Melbourne - Epworth Freemasons (1)
3051 - Melbourne - Australian Prostate Centre (1)
3066 - Epping - Northern Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4655 - Urraween - Cancer Care Service, Hervey Bay Hospital (1)
4670 - Bundaberg - Bundaberg Hospital, Genesis Cancer Care (1)
NA
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
5065 - Toorak Gardens - Burnside War Memorial Hospital (1)
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre (1)
2060 - North Sydney - Mater Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
Cancer Type
Cancer
Solid tumour
Urogenital cancer
Melanoma
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Breast cancer
Carcinoma
Male genital cancers
Prostate cancer
Bladder cancer
Cervical cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Haematological malignancy
Viral-related cancer
Castrate-resistant prostate cancer
Prostate adenocarcinoma
B-cell lymphoma
B-cell malignancy
Breast adenocarcinoma
Diffuse large B-cell lymphoma
Follicular lymphoma
Head and neck cancer
Head and neck squamous cell carcinoma
High-grade B-cell lymphoma
Lymphoma
Mantle cell lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Skin cancer
Triple-negative breast cancer
Uveal melanoma
FGFR3:alteration
Urothelial carcinoma
Epithelial Ovarian Cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
High-grade serous ovarian cancer
Neuroendocrine carcinoma
Ovarian adenocarcinoma
Ovarian cancer
Ovarian serous carcinoma
Platinum resistant ovarian cancer
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy